{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:06:53Z","timestamp":1766048813206},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1097\/md.0000000000006970","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T15:56:57Z","timestamp":1495641417000},"page":"e6970","source":"Crossref","is-referenced-by-count":32,"title":["Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis"],"prefix":"10.1097","volume":"96","author":[{"given":"Ya-Kang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Qing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Bin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-37-20210309","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J Bone Miner Res"},{"key":"R2-37-20210309","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.","volume":"843","year":"1994","journal-title":"World Health Organ Tech Rep Ser"},{"key":"R3-37-20210309","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int"},{"key":"R4-37-20210309","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ecl.2005.01.014","article-title":"Osteoporosis associated with excess glucocorticoids","volume":"34","author":"Shaker","year":"2005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R5-37-20210309","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1001\/archinte.1991.00400100100017","article-title":"A model of lifetime osteoporosis impact","volume":"151","author":"Chrischilles","year":"1991","journal-title":"Arch Intern Med"},{"key":"R6-37-20210309","first-page":"114","article-title":"Appropriate use of anabolic treatment for severe osteoporosis","volume":"7","author":"Adami","year":"2010","journal-title":"Clin Cases Miner Bone Metab"},{"key":"R7-37-20210309","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1749-6632.2010.05666.x","article-title":"Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis","volume":"1205","author":"Lyritis","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"R8-37-20210309","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","article-title":"New insights into the molecular mechanisms of action of bisphosphonates","volume":"9","author":"Rogers","year":"2003","journal-title":"Curr Pharm Des"},{"key":"R9-37-20210309","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S8756-3282(98)00033-7","article-title":"Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo","volume":"22","author":"Giuliani","year":"1998","journal-title":"Bone"},{"key":"R10-37-20210309","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"R11-37-20210309","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial","volume":"44","author":"Adachi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R12-37-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R13-37-20210309","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-37-20210309","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R15-37-20210309","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"R16-37-20210309","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1359\/jbmr.061011","article-title":"Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis","volume":"22","author":"Keaveny","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R17-37-20210309","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-37-20210309","doi-asserted-by":"crossref","first-page":"CR442","DOI":"10.12659\/MSM.881905","article-title":"Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life","volume":"17","author":"Panico","year":"2011","journal-title":"Med Sci Monit"},{"key":"R19-37-20210309","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70\u200amg once-weekly and alendronate 10\u200amg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano"},{"key":"R20-37-20210309","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","article-title":"Patient preference for once-weekly alendronate 70\u200amg versus once-daily alendronate 10\u200amg: a multicenter, randomized, open-label, crossover study","volume":"24","author":"Simon","year":"2002","journal-title":"Clin Ther"},{"key":"R21-37-20210309","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/gme.0b013e3181c617e6","article-title":"Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society.","volume":"17","year":"2010","journal-title":"Menopause"},{"key":"R22-37-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9220","article-title":"A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis","volume":"9","author":"Stevenson","year":"2005","journal-title":"Health Technol Assess"},{"key":"R23-37-20210309","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1742-1241.2011.02837.x","article-title":"Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials","volume":"66","author":"Han","year":"2012","journal-title":"Int J Clin Pract"},{"key":"R24-37-20210309","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.12659\/MSM.892581","article-title":"Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs","volume":"20","author":"Song","year":"2014","journal-title":"Med Sci Monit"},{"key":"R25-37-20210309","doi-asserted-by":"crossref","first-page":"e26267","DOI":"10.1371\/journal.pone.0026267","article-title":"Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials","volume":"6","author":"Shen","year":"2011","journal-title":"PLoS ONE"},{"key":"R26-37-20210309","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"R27-37-20210309","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"R28-37-20210309","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"key":"R29-37-20210309","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"R30-37-20210309","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R31-37-20210309","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1210\/jc.2003-1703","article-title":"Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy","volume":"90","author":"Dobnig","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-37-20210309","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1590\/S1516-31802008000500007","article-title":"Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review","volume":"126","author":"Trevisani","year":"2008","journal-title":"Sao Paulo Med J"},{"key":"R33-37-20210309","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jama.1997.03540380073035","article-title":"Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups","volume":"277","author":"Karpf","year":"1997","journal-title":"JAMA"},{"key":"R34-37-20210309","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3111\/13696998.2010.499072","article-title":"Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis","volume":"13","author":"Borgstr\u00f6m","year":"2010","journal-title":"J Med Econ"},{"key":"R35-37-20210309","doi-asserted-by":"crossref","first-page":"734","DOI":"10.7326\/0003-4819-142-9-200505030-00008","article-title":"Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women","volume":"142","author":"Schousboe","year":"2005","journal-title":"Ann Intern Med"},{"key":"R36-37-20210309","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1471-2474-13-213","article-title":"The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden","volume":"13","author":"Murphy","year":"2012","journal-title":"BMC Musculoskelet Disord"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000006970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:50:30Z","timestamp":1620960630000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201705260-00037"}},"subtitle":["A meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":36,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000006970","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}